NEONC TECHNOLOGIES HOLDINGS, INC.
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | $40K-51.8% | $83K |
| Research and development | $3.6M+19.5% | $3.0M |
| Legal and professional | $2.5M+24.0% | $2.0M |
| General and administrative | $4.8M+186.8% | $1.7M |
| Share based compensation | $35.6M | — |
| Advisory fees – principally related parties | $11.8M+2257.6% | $500K |
| Total Operating Expenses | $58.3M+706.6% | $7.2M |
| Loss From Operations | -$58.2M-715.4% | -$7.1M |
| Interest and other income | $328K+1930.5% | $16K |
| Grant income | $71K | — |
| Amortization of debt issuance costs | -$1.1M-665.3% | -$145K |
| Interest expense | -$2.5M+2.1% | -$2.6M |
| Loss on extinguishment of Bridge loan – related party | -$2.1M | — |
| Loss on change in fair value of derivative liability related to sales of common stock through equity line of credit | -$690K | — |
| Net Loss | -$62.1M-422.3% | -$11.9M |
| Basic net loss per common share | -$3.20-363.8% | -$0.69 |
| Diluted net loss per common share | -$3.20-363.8% | -$0.69 |
| Weighted average shares used in computing basic net loss per common share | $19398776.00+11.9% | $17342755.00 |
| Weighted average shares used in computing diluted net loss per common share | $19398776.00+11.9% | $17342755.00 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
NeOnc reported Q1 2026 net loss of $0.38 per diluted share on $8.8M net loss, completed Phase 1 for NEO212 with RP2D established, and secured PIPE financing to fund operations into September 2026
“The first quarter of 2026 marked a transformational period for NeOnc as we advanced both of our lead clinical programs toward important regulatory and value-creation milestones.”
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | 2026-05-04 | Heshmatpour Amir F | Director & President | Purchase | 10.0K | $4.16 | $42K | 3.07M | View | |
| 2026-04-28 | 2026-04-28 | Heshmatpour Amir F | Director & President | Purchase | 10.0K | $4.52 | $45K | 3.06M | View | |
| 2026-04-23 | 2026-04-24 | Neman-Ebrahim Yousha | Chief Clinical Officer | Purchase | 500 | $4.88 | $2K | 134.8K | View | |
| 2025-04-15 | 2026-04-24 | GARNETT KEITHLY | CFO | Purchase | 300 | $5.38 | $2K | 241.2K | View | |
| 2026-04-23 | 2026-04-23 | Heshmatpour Amir F | Director & President | Purchase | 10.0K | $4.90 | $49K | 3.05M | View |
Informational purposes only, not investment advice.